日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Access to Chimeric Antigen Receptor T-Cell Therapy in Patients With Diffuse Large B-Cell Lymphoma

弥漫性大B细胞淋巴瘤患者接受嵌合抗原受体T细胞疗法的机会

Patel, Anik R; Hsu, Hil; Lau, Constance; Perales, Miguel-Angel; Basu, Anirban

Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis

美国复发/难治性弥漫性大B细胞淋巴瘤患者CAR-T细胞疗法获取方面的不平等:基于SEER-Medicare数据的分析

Chung, Andrea P; Shafrin, Jason T; Vadgama, Sachin; Hurley, Kristen; Perales, Miguel-Angel; Alsfeld, Leonard C; Muthukrishnan, Sanjana; Patel, Anik R; Shah, Gunjan L; Maziarz, Richard T

The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis

POD24在复发/难治性滤泡性淋巴瘤中的预后价值——一项SCHOLAR-5分析

Limbrick-Oldfield, Eve H; Kanters, Steve; Ray, Markqayne D; Best, Timothy; Palivela, Madhu; Beygi, Sara; Patel, Anik R; Gribben, John G; Ghione, Paola

Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysis

不同医疗机构中接受嵌合抗原受体T细胞疗法治疗的弥漫性大B细胞淋巴瘤患者的医疗资源利用情况和费用:一项真实世界数据分析

Patel, Anik R; Hasegawa, Ken; Pandya, Shivani; Shi, Liucheng; Lau, Constance; Zhao, Xiaohui; Near, Aimee M; Locke, Frederick L

A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States

美国弥漫性大B细胞淋巴瘤治疗路径的成本效益分析

Patel, Anik R; Kievit, Bradley; Hasegawa, Ken; Ray, Markqayne; Sharma, Rishika; Hofmann, Sarahmaria; Blissett, Rob; Locke, Frederick L

Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States

在美国,使用axicabtagene ciloleucel与mosunetuzumab治疗复发或难治性3L+滤泡性淋巴瘤的成本效益分析

Oluwole, Olalekan O; Ray, Markqayne D; Zur, Richard M; Ferrufino, Cheryl P; Doble, Brett; Patel, Anik R; Bilir, S Pinar

An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States

美国二线大B细胞淋巴瘤患者使用axicabtagene ciloleucel的最新成本效益分析

Oluwole, Olalekan O; Patel, Anik R; Vadgama, Sachin; Smith, Nathaniel J; Blissett, Rob; Feng, Chaoling; Dickinson, Michael; Johnston, Patrick B; Perales, Miguel-Angel

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study

复发/难治性滤泡性淋巴瘤的治疗模式和结果:来自国际 SCHOLAR-5 研究的结果

Ghione, Paola; Palomba, M Lia; Ghesquieres, Hervé; Bobillo, Sabela; Patel, Anik R; Nahas, Myrna; Kanters, Steve; Deighton, Kevin; Hatswell, Anthony; Ma, Long; Limbrick-Oldfield, Eve H; Snider, Julia Thornton; Wade, Sally W; Riberio, Maria Teresa; Radford, John; Beygi, Sara; Gribben, John

Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma

复发/难治性滤泡性淋巴瘤的比较疗效和成本效益研究中需要进行风险调整

Gribben, John; Palomba, M Lia; Patel, Anik R; Nahas, Myrna; Neelapu, Sattva S

Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis

滤泡性淋巴瘤患者在接受≥2线既往治疗后复发/难治性治疗的临床结局:系统性文献综述和荟萃分析

Kanters, Steve; Ball, Graeme; Kahl, Brad; Wiesinger, Adriana; Limbrick-Oldfield, Eve H; Sudhindra, Akshay; Snider, Julia Thornton; Patel, Anik R